Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world?

van Bogaert Lj.

Ann Med Health Sci Res. 2013 Jul;3(3):306-12. doi: 10.4103/2141-9248.117924. Review.

2.

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ.

BMC Infect Dis. 2013 Feb 7;13:75. doi: 10.1186/1471-2334-13-75.

4.

Cost-effectiveness of different human papillomavirus vaccines in Singapore.

Lee VJ, Tay SK, Teoh YL, Tok MY.

BMC Public Health. 2011 Mar 31;11:203. doi: 10.1186/1471-2458-11-203.

5.

The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.

Brinkman JA, Caffrey AS, Muderspach LI, Roman LD, Kast WM.

Eur J Gynaecol Oncol. 2005;26(2):129-42. Review.

PMID:
15857016
6.

[What should be known for the introduction of an HPV vaccine?].

Muñoz N, Jacquard AC.

Presse Med. 2008 Oct;37(10):1377-90. doi: 10.1016/j.lpm.2008.04.008. Epub 2008 Sep 10. Review. French.

PMID:
18786806
7.

[Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].

Bégué P, Henrion R, Blanc B, Girard M, Sancho-Garnier H.

Bull Acad Natl Med. 2007 Dec;191(9):1805-16; discussion 1816-7. French.

PMID:
18663976
8.

Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.

Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.

Arch Med Res. 2009 Aug;40(6):503-13. doi: 10.1016/j.arcmed.2009.08.004.

PMID:
19853192
9.

Human papillomavirus vaccination in adolescence.

Russell M, Raheja V, Jaiyesimi R.

Perspect Public Health. 2013 Nov;133(6):320-4. doi: 10.1177/1757913913499091. Epub 2013 Sep 4. Review.

PMID:
24006173
10.

Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.

Capri S, Gasparini R, Panatto D, Demarteau N.

Gynecol Oncol. 2011 Jun 1;121(3):514-21. doi: 10.1016/j.ygyno.2011.01.029. Epub 2011 Feb 19.

PMID:
21334734
11.

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

Demarteau N, Van Kriekinge G, Simon P.

Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15.

12.

Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.

McIntosh J, Sturpe DA, Khanna N.

J Am Pharm Assoc (2003). 2008 Jan-Feb;48(1):e1-13; quiz e14-7. doi: 10.1331/JAPhA/2008.07032. Review.

PMID:
18192123
13.

[Human papillomavirus vaccines].

Brun JL.

J Gynecol Obstet Biol Reprod (Paris). 2008 Feb;37 Suppl 1:S155-66. doi: 10.1016/j.jgyn.2007.11.019. Epub 2008 Jan 9. Review. French.

14.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.

PMID:
19819540
15.
16.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

17.

Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.

Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.

Vaccine. 2013 Aug 20;31(37):3863-71. doi: 10.1016/j.vaccine.2013.06.064. Epub 2013 Jul 3.

PMID:
23830974
18.

Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.

Julius JM, Ramondeta L, Tipton KA, Lal LS, Schneider K, Smith JA.

Pharmacotherapy. 2011 Mar;31(3):280-97. doi: 10.1592/phco.31.3.280. Review.

PMID:
21361739
19.

Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors.

Damm O, Nocon M, Roll S, Vauth C, Willich S, Greiner W.

GMS Health Technol Assess. 2009 Mar 11;5:Doc04. doi: 10.3205/hta000066.

20.

Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.

Kiatpongsan S, Kim JJ.

PLoS One. 2014 Sep 8;9(9):e106836. doi: 10.1371/journal.pone.0106836. eCollection 2014.

Supplemental Content

Support Center